|
PTCD2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62536650805123E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.0325074129014E-14 |
| Normal-vs-Stage2 |
6.521500E-03 |
| Normal-vs-Stage3 |
9.57123269529347E-13 |
| Normal-vs-Stage4 |
3.10451664375933E-12 |
| Stage1-vs-Stage2 |
1.132230E-02 |
| Stage1-vs-Stage3 |
1.554220E-01 |
| Stage1-vs-Stage4 |
1.118370E-02 |
| Stage2-vs-Stage3 |
2.097400E-03 |
| Stage2-vs-Stage4 |
2.558000E-04 |
| Stage3-vs-Stage4 |
3.056200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.66533453693773E-15 |
| Normal-vs-AfricanAmerican |
3.70900000000729E-05 |
| Normal-vs-Asian |
1.18600018694792E-10 |
| Caucasian-vs-AfricanAmerican |
6.468000E-01 |
| Caucasian-vs-Asian |
4.629400E-01 |
| AfricanAmerican-vs-Asian |
3.599200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.43398659402783E-12 |
| Normal-vs-Female |
1.63302704692114E-12 |
| Male-vs-Female |
3.063800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.33099975485607E-10 |
| Normal-vs-Age(41-60Yrs) |
1.96698213272839E-12 |
| Normal-vs-Age(61-80Yrs) |
9.3821999946897E-08 |
| Normal-vs-Age(81-100Yrs) |
1.151400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.056600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.722240E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.125200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.785400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.226200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.364790E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.086000E-02 |
| Classical-VS-Follicular |
1.74032999999962E-05 |
| Classical-VS-Other |
6.747000E-01 |
| Classical-VS-Normal |
6.62000454454414E-11 |
| Tall-VS-Follicular |
2.59659999946038E-07 |
| Tall-VS-Other |
6.954000E-01 |
| Tall-VS-Normal |
2.41751063612128E-12 |
| Follicular-VS-Other |
8.785700E-02 |
| Follicular-VS-Normal |
1.960070E-03 |
| Other-VS-Normal |
1.561970E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.22760024368063E-10 |
| Normal-vs-N1 |
1.66555658154266E-12 |
| N0-vs-N1 |
1.751849999998E-05 |
|
|
